Clinical

Despite a greater risk of cardiovascular disease (CVD) due to exposure to chemotherapy and/or radiation, adult survivors of childhood cancer are undertreated for CVD risk factors compared with the general population.

During a session at the 2022 European Hematology Association Congress, speakers discussed how artificial intelligence (AI) can help advance the principles of ethical medicine—but also how new technologies are being used to undermine the integrity of scientific research.

The investigators cautioned, however, that the factors identified had only modest predictive power.

Abstracts presented at the 2022 European Hematology Association Congress demonstrate superior health-related quality of life (HRQOL) outcomes among patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) taking zanubrutinib.

Physicians should consider measuring anti-endothelial cell antibodies in patients with polycythemia vera, the investigators suggested.

The long-term study also found persistent residual risk of heart failure even after smoking cessation

Using biosimilar rituximab to replace the reference in a common combination regimen to treat diffuse large B-cell lymphoma (DLBCL) results in similar outcomes.

Finding therapeutic targets for acute myeloid leukemia (AML) has proven challenging, but a set of immune-regulating molecules may hold promise as biomarkers and targets.

In abstracts featured at the 2022 European Hematology Association Congress, investigators detailed long-term results of the ASPEN phase 3 trial and an expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia (WM).

GlaxoSmithKline (GSK) aims to have its respiratory syncytial virus (RSV) vaccine reviewed later this year; Northwell Health and Kaiser Permanente among CEOs supporting gun legislation; Infants whose mothers had COVID-19 during their pregnancy had double the risk of delayed speech or motor skills.

A systematic review and meta-analysis found no clear advantage for automated red cell exchange.

An education session at the 2022 European Hematology Association Congress featured updates on using genetic and immune characteristics to select the optimal treatment pathway in chronic lymphocytic leukemia (CLL).

Abstracts presented at EULAR 2022 focused on sex-related differences in inflammatory arthritis (IA) management, including adherence to electronically reporting outcomes and disparities in health care utilization.

Study data are mixed, but some evidence suggests the administration of vitamin D may work as a low-risk prophylactic against graft-versus-host disease (GVHD).

Hepatobiliary-phase enhanced imaging outperformed diffusion-weighted imaging in distinguishing intrahepatic mass-forming cholangiocarcinoma, but the accuracy is greater when these methods are used in tandem.

Real-world studies evaluating the safety and efficacy of switching to adalimumab biosimilars from the originator product confirmed the safety and efficacy of the biosimilars ABP 501 and SB5.

A new study found that patients with e-cigarette or vaping–associated lung injury had a higher risk of developing respiratory disability, cognitive impairment, symptoms of depression, anxiety, and posttraumatic stress within 1 year of their injury.

A new model may be able to better identify which patients will respond to immunotherapy.

The FDA this week expanded the use of dupilumab for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) whose disease is not controlled with topical prescription therapies or when those treatments can't be used.

The study, based on 33 years of data, also explored auto-antibody production in the rare patient group.

The 2022 European Hematology Association (EHA) Congress will be the group’s first hybrid meeting, in which investigators will convene both virtually and in Vienna, Austria, from June 9-12, 2022, to present cutting-edge findings in the realm of oncology and hematology.

Identifying patients with spinal muscular atrophy (SMA) early and before the onset of symptoms can yield financial savings and improve quality of life (QOL) for these individuals and their families.

The results involve a pair of DNA medicines combined with cemiplimab, which is approved as Libtayo to treat other solid tumors. In this study, the regimen is designed to prime a T-cell response before a patient receives radiation.

Dr Jonathan L. Kaufman discusses the role immunomodulatory drugs (IMiDs) play within triplet regimens for patients with RRMM.

Joshua Richter, MD, and Jonathan L. Kaufman, MD, define and provide a basic understanding of relapsed/refractory multiple myeloma (RRMM).